[HTML][HTML] Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases
BP Dixon, LA Greenbaum, L Huang, S Rajan… - Kidney International …, 2023 - Elsevier
Introduction Dysregulated complement activation is likely the primary driver of disease in C3
glomerulopathy (C3G) and contributes to other complement-mediated diseases, including …
glomerulopathy (C3G) and contributes to other complement-mediated diseases, including …
[HTML][HTML] Efficacy and safety of iptacopan in patients with C3 glomerulopathy
Introduction Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
mediated by dysregulation of the alternative complement pathway. No targeted therapy …
# 277 Update to the long-term safety and efficacy of iptacopan in C3G: 33-month extension study data from patients enrolled in a phase 2 study
CM Nester, U Eisenberger, A Karras… - Nephrology Dialysis …, 2024 - academic.oup.com
Abstract Background and Aims Complement 3 glomerulopathy (C3G), due to dysregulation
of the alternative complement pathway (AP), is an ultra-rare primary glomerulonephritis …
of the alternative complement pathway (AP), is an ultra-rare primary glomerulonephritis …
[HTML][HTML] Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial
AS Bomback, D Kavanagh, M Vivarelli, M Meier… - Kidney International …, 2022 - Elsevier
Introduction Complement 3 glomerulopathy (C3G) is a rare kidney disease characterized by
dysregulation of the alternative pathway (AP) of the complement system. About 50% of …
dysregulation of the alternative pathway (AP) of the complement system. About 50% of …
Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases
MS Meuleman, A Grunenwald, S Chauvet - Seminars in Immunology, 2022 - Elsevier
Abstract C3 glomerulopathy (C3G) is a rare and complex kidney disease that primarily
affects young adults. Renal outcomes remain poor in the absence of specific treatment. C3G …
affects young adults. Renal outcomes remain poor in the absence of specific treatment. C3G …
[HTML][HTML] Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies
C Nester, GB Appel, AS Bomback… - American journal of …, 2022 - karger.com
Abstract Introduction: C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive
nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with …
nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with …
[PDF][PDF] Iptacopan, a novel oral complement factor B (FB) inhibitor, significantly reduces proteinuria and C3 deposit scores in native and transplanted kidneys C3 …
EKS Wong, C Nester… - J Am Soc …, 2021 - medcommshydhosting.com
Iptacopan, a novel oral complement Factor B (FB) inhibitor, significantly reduces proteinuria
and C3 Deposit Scores in native an Page 1 Confidential – For Internal Use Only Iptacopan, a …
and C3 Deposit Scores in native an Page 1 Confidential – For Internal Use Only Iptacopan, a …
[HTML][HTML] C3 glomerulopathy and current dilemmas
N Ito, R Ohashi, M Nagata - Clinical and experimental nephrology, 2017 - Springer
Abstract C3 glomerulopathy (C3G) is a recently identified disease entity caused by
dysregulation of the alternative complement pathway, and dense deposit disease (DDD) …
dysregulation of the alternative complement pathway, and dense deposit disease (DDD) …
Baseline clinical characteristics and complement biomarkers of patients with C3 glomerulopathy enrolled in two phase 2 studies investigating the factor D inhibitor …
SD Podos, H Trachtman, GB Appel… - American Journal of …, 2023 - karger.com
Abstract Introduction: C3 glomerulopathy (C3G) is a rare, progressive kidney disease
resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at …
resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at …
[HTML][HTML] C3 Glomerulopathy: Novel Treatment Paradigms
BT Estebanez, AS Bomback - Kidney International Reports, 2023 - Elsevier
Abstract C3 glomerulopathy (C3G) is diagnosed by kidney biopsy, with immunofluorescence
showing isolated or dominant C3 staining, indicating hyperactivity of the alternative …
showing isolated or dominant C3 staining, indicating hyperactivity of the alternative …